oncolex logo
Utskriftsdato 3.4.2020

Referanser til kreft med ukjent utgangspunkt

  1. Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: population-based analysis by site and histology. (2012) Ann Oncol; 23: 1854-63.
  2. Pavlidis N, Pentheroudakis G. (2012) Cancer of unknown primary site. The Lancet. 14; 379: 1428-35.
  3. Bahrami A, Truong LD, Ro JY. (2008) Undifferentiated tumor: true identity by immunohistochemistry. Arch Pathol Lab Med; 132: 326-48.
  4. Pentheroudakis G, Golfinopoulos V, Pavlidis N. (2007) Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer; 43: 2026-36.
  5. Jerusalem G, Rorive A, Ancion G, Hustinx R, Fillet G. (2006) Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations. Ann Oncol; 17 Suppl 10: x168–76
  6. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G; ESMO Guidelines Working Group. (2011) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol; 22 Suppl 6:vi64-8.
  7. Pavlidis N. (2012) Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets. Ann Oncol; 23 Suppl 10:x282-x285.
  8. Cancer in Norway 2018, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway
  9. Brustugun OT, Helland Å. (2014) Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta Oncol; Jan 53(1):134-7.